Article
How Biomarker Testing Drives the Use of Targeted Therapies
ONS member Cyndy Simonson, MS, APRN-BC, AOCN®, oncology nurse practitioner who is the nursing editor at Duke Regional Hospital in Durham, NC, and member of the North Carolina Triangle ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss biomarker testing for patients with cancer and how it affects targeted therapy regimens during treatment. The advertising messages in this episode are paid for by G1 Therapeutics, Inc.
Related Topics
You May Also Like
Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
Article